7-methoxy-1-methyl-2,3,4,4a,9,9a-hexahydro-1H-pyrido[3,4-b]indole | 34432-20-7

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 英文名称: 7-methoxy-1-methyl-2,3,4,4a,9,9a-hexahydro-1H-pyrido[3,4-b]indole
• CAS: 34432-20-7
• 化学式: C₁₃H₁₈N₂O
• 分子量: 218.299
• InChiKey: FTQXELOPBMFYKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  33.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  肉叶云香碱 在 甲醇 、 sodium tetrahydroborate 、 palladium on activated charcoal 、 氢气 作用下， 以 2,2,2-三氟乙醇 、 乙酸乙酯 为溶剂， 反应 27.0h， 生成 7-methoxy-1-methyl-2,3,4,4a,9,9a-hexahydro-1H-pyrido[3,4-b]indole
  参考文献：
  名称：

  Synthesis and Antiviral and Fungicidal Activity Evaluation of β-Carboline, Dihydro-β-carboline, Tetrahydro-β-carboline Alkaloids, and Their Derivatives

  摘要：

  Six known beta-carboline, dihydro-beta-carboline, and tetrahydro-beta-carboline alkaloids and a series of their derivatives were designed, synthesized, and evaluated for their anti-tobacco mosaic virus (TMV) and fungicidal activities for the first time. All of the alkaloids and some of their derivatives (compounds 3, 4, 14, and 19) exhibited higher anti-TMV activity than the commercial antiviral agent Ribavirin both in vitro and in vivo. Especially, the inactivation, curative, and protection activities of alkaloids Harmalan (62.3, 55.1, and 60.3% at 500 mu g/mL) and tetrahydroharmane (64.2, 57.2, and 59.5% at 500 mu g/mL) in vivo were much higher than those of Ribavirin (37.4, 36.2, and 38.5% at 500 mu g/mL). A new derivative, 14, with optimized physicochemical properties, obviously exhibited higher activities in vivo (50.4, 43.9, and 47.9% at 500 mu g/mL) than Ribavirin and other derivatives; therefore, 14 can be used as a new lead structure for the development of anti-TMV drugs. Moreover, most of these compounds exhibited good fungicidal activity against 14 kinds of fungi, especially compounds 4, 7, and 11.

  DOI：

  10.1021/jf404840x

文献信息

• SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR
  申请人：Diamond Marc

  公开号：US20100168128A1

  公开（公告）日：2010-07-01

  The present invention provides a method of inhibiting an androgen receptor by administering a compound of Formula I: or a compound of Formula II: wherein R 1 , R 2 , R 3 and R 8 are each independently hydrogen or C 1-6 alkyl. R 4 is absent or is hydrogen, C 1-6 alkyl or C 1-6 alkyl-OH. R 5 is hydrogen, C 1-6 alkyl or —NR 6 R 7 . R 6 and R 7 are each independently hydrogen or C 1-6 alkyl, or are combined with the nitrogen to which they are attached to form a heterocycloalkyl having from 5 to 7 ring members. L is a linker of C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene or C 3-6 cycloalkylene. The compounds of Formula I include the salts, hydrates and prodrugs thereof. Each R 9 is H, C 1-6 alkyl, —OH or —O—C 1-6 alkyl. The compounds of Formulas I and II include the salts, hydrates and prodrugs thereof. By administering the compound of Formula I or II, the method inhibits the androgen receptor.

  本发明提供了一种通过给予公式I的化合物或公式II的化合物来抑制雄激素受体的方法：其中R1、R2、R3和R8各自独立地是氢或C1-6烷基，R4不存在或为氢、C1-6烷基或C1-6烷基-OH，R5是氢、C1-6烷基或—NR6R7，R6和R7各自独立地是氢或C1-6烷基，或与它们所连接的氮结合形成具有5至7个环成员的杂环烷基。L是C1-6烷基、C2-6烯基、C2-6炔基或C3-6环烷基的连接基。公式I的化合物包括其盐、水合物和前药。每个R9是H、C1-6烷基、—OH或—O—C1-6烷基。公式I和II的化合物包括其盐、水合物和前药。通过给予公式I或II的化合物，该方法抑制雄激素受体。
• US8119660B2
  申请人：——

  公开号：US8119660B2

  公开（公告）日：2012-02-21